Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer

References

• GarciaMJemalAWardEMGlobal Cancer Facts and Figures 2007Atlanta, GAAmerican Cancer Society2007
   Google Scholar
• American Cancer SocietyCancer Facts and Figures 2010Atlanta, GAAmerican Cancer Society2010
   Google Scholar
• ColemanRESkeletal complications of malignancyCancer1997808 Suppl158815949362426
   PubMed Web of Science ®Google Scholar
• SaadFLiptonACookRChenYMSmithMColemanRPathologic fractures correlate with reduced survival in patients with malignant bone diseaseCancer200711081860186717763372
   PubMed Web of Science ®Google Scholar
• ClezardinPFournierPBoissierSPeyruchaudOIn vitro and in vivo antitumor effects of bisphosphonatesCurr Med Chem200310217318012570716
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyLancet Oncol20089984084918718815
   PubMed Web of Science ®Google Scholar
• HaTCLiHMeta-analysis of clodronate and breast cancer survivalBr J Cancer200796121796180117325699
   PubMed Web of Science ®Google Scholar
• HershmanDLMcMahonDJCrewKDZoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancerJ Clin Oncol200826294739474518711172
   PubMed Web of Science ®Google Scholar
• PavlakisNSchmidtRStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20053CD00347416034900
   PubMed Web of Science ®Google Scholar
• BerensonJRLichtensteinAPorterLLong-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study GroupJ Clin Oncol19981625936029469347
   PubMed Web of Science ®Google Scholar
• BerensonJRRosenLSHowellAZoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer20019171191120011283917
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitserMRIntravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastasesAnn Oncol20031491399140512954579
   PubMed Web of Science ®Google Scholar
• BodyJJDielIJLichinitzerMOral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBr J Cancer20049061133113715026791
   PubMed Web of Science ®Google Scholar
• BrinckerHWestinJAbildgaardNFailure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study groupBr J Haematol199810122802869609523
   PubMed Web of Science ®Google Scholar
• DearnaleyDPSydesMRMasonMDA double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)J Natl Cancer Inst200395171300131112953084
   PubMed Web of Science ®Google Scholar
• GimsingPCarlsonKTuressonIEffect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trialLancet Oncol2010111097398220863761
   PubMed Web of Science ®Google Scholar
• KohnoNAogiKMinamiHZoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialJ Clin Oncol200523153314332115738536
   PubMed Web of Science ®Google Scholar
• KristensenBEjlertsenBGroenvoldMHeinSLoftHMouridsenHTOral clodronate in breast cancer patients with bone metastases: a randomized studyJ Intern Med19992461677410447227
   PubMed Web of Science ®Google Scholar
• LahtinenRLaaksoMPalvaIVirkkunenPElomaaIRandomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia GroupLancet19923408827104910521357451
   PubMed Web of Science ®Google Scholar
• LiptonATheriaultRLHortobagyiGNPamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trialsCancer20008851082109010699899
   PubMed Web of Science ®Google Scholar
• McCloskeyEVMacLennanICDraysonMTChapmanCDunnJKanisJAA randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in AdultsBr J Haematol199810023173259488619
   PubMed Web of Science ®Google Scholar
• MenssenHDSakalovaAFontanaAEffects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myelomaJ Clin Oncol20022092353235911981007
   PubMed Web of Science ®Google Scholar
• PatersonAHPowlesTJKanisJAMcCloskeyEHansonJAshleySDouble-blind controlled trial of oral clodronate in patients with bone metastases from breast cancerJ Clin Oncol199311159658418243
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMZoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J20017537738711693896
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• RosenLSGordonDTchekmedyianSZoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial – the Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJ Clin Oncol200321163150315712915606
   PubMed Web of Science ®Google Scholar
• SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
   PubMed Web of Science ®Google Scholar
• SmallEJSmithMRSeamanJJPetroneSKowalskiMOCombined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancerJ Clin Oncol200321234277428414581438
   PubMed Web of Science ®Google Scholar
• Tubiana-HulinMBeuzebocPMauriacLDouble-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastasesBull Cancer200188770170711495824
   PubMed Web of Science ®Google Scholar
• Zometa [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2009
   Google Scholar
• Aredia [prescribing information]East Hanover, NJNovartis Pharmaceuticals Corporation2008
   Google Scholar
• Xgeva [prescribing information]Thousand Oaks, CAAmgen Inc2010
   Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in OncologyBreast Cancer V.2.2011www.nccn.org2010 Updated December 6, 2010Accessed January 5, 2011
   Google Scholar
• ClezardinPAnti-tumour activity of zoledronic acidCancer Treat Rev200531Suppl 31816225995
   PubMed Web of Science ®Google Scholar
• GnantMBisphosphonates in the prevention of disease recurrence: current results and ongoing trialsCurr Cancer Drug Targets20099782483320025570
   PubMed Web of Science ®Google Scholar
• MeadsMBHazlehurstLADaltonWSThe bone marrow microenvironment as a tumor sanctuary and contributor to drug resistanceClin Cancer Res20081492519252618451212
   PubMed Web of Science ®Google Scholar
• BrownJECookRJMajorPBone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJ Natl Cancer Inst2005971596915632381
   PubMed Web of Science ®Google Scholar
• ColemanREMajorPLiptonAPredictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidJ Clin Oncol200523224925493515983391
   PubMed Web of Science ®Google Scholar
• LiptonACookRJMajorPSmithMRColemanREZoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activityOncologist20071291035104317914073
   PubMed Web of Science ®Google Scholar
• LiptonACookRSaadFNormalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer2008113119320118459173
   PubMed Web of Science ®Google Scholar
• ZaghloulMSBoutrusREl-HossienyHKaderYAEl-AttarINazmyMA prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancerInt J Clin Oncol201015438238920354750
   PubMed Web of Science ®Google Scholar
• AvilesANamboMJNeriNCastanedaCCletoSHuerta-GuzmanJAntitumor effect of zoledronic acid in previously untreated patients with multiple myelomaMed Oncol200724222723017848748
   PubMed Web of Science ®Google Scholar
• MorganGJDaviesFEGregoryWMNational Cancer Research Institute Haematological Oncology Clinical Study GroupFirst-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialLancet201037697571989199921131037
   PubMed Web of Science ®Google Scholar
• PadmanabhanNWangDYMooreJWRubensRDOvarian function and adjuvant chemotherapy for early breast cancerEur J Cancer Clin Oncol19872367457483653192
   PubMedGoogle Scholar
• PfeilschifterJDielIJOsteoporosis due to cancer treatment: pathogenesis and managementJ Clin Oncol20001871570159310735906
   PubMed Web of Science ®Google Scholar
• GnantMFMlineritschBLuschin-EbengreuthGZoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study GroupJ Clin Oncol200725782082817159195
   PubMed Web of Science ®Google Scholar
• EastellRAdamsJEColemanREEffect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230J Clin Oncol20082671051105718309940
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBStoegerHMature results from ABCSG-12: Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive early breast cancerPresented at 46th Annual Meeting of the American Society of Clinical Oncology (ASCO)June 4–8, 2010Chicago, IL Abstract 533
   Google Scholar
• OttewellPDDeuxBMonkkonenHDifferential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivoClin Cancer Res200814144658466618628481
   PubMed Web of Science ®Google Scholar
• AftRNaughtonMTrinkausKEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialLancet Oncol201011542142820362507
   PubMed Web of Science ®Google Scholar
• GreenbergSParkJWMeliskoMEEffect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): updated resultsPresented at 46th Annual Meeting of the American Society of Clinical OncologyJune 4–8, 2010Chicago, IL Abstract 1002
   Google Scholar
• RackBJuckstockJGenssEMEffect of zoledronate on persisting isolated tumour cells in patients with early breast cancerAnticancer Res20103051807181320592383
   PubMed Web of Science ®Google Scholar
• SolomayerEFGebauerGHirnlePInfluence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patientsPresented at 31st Annual San Antonio Breast Cancer SymposiumDecember 10–14, 2008San Antonio, TX Abstract 2048
   Google Scholar
• JanniWRackBSchindlbeckCThe persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrenceCancer2005103588489115666325
   PubMed Web of Science ®Google Scholar
• SchindlbeckCKampikTJanniWPrognostic relevance of disseminated tumor cells in the bone marrow and biological factors of 265 primary breast carcinomasBreast Cancer Res200576R1174R118516457698
   PubMed Web of Science ®Google Scholar
• LinAYParkJWScottJZoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrowJ Clin Oncol200826Suppl20s Abstract 559
   PubMed Web of Science ®Google Scholar
• Neville-WebbeHLColemanREHolenICombined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interactionBr J Cancer201010261010101720160726
   PubMed Web of Science ®Google Scholar
• EidtmannHde BoerRBundredNEfficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyAnn Oncol201021112188219420444845
   PubMed Web of Science ®Google Scholar
• LlombartAFrassoldatiAPaijaOZoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-upPresented at 2009 ASCO Breast Cancer SymposiumOctober 8–10, 2009San Francisco, CA Abstract 213
   Google Scholar
• FrassoldatiABrufskyABundredNEffect of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: a 24-month integrated follow-up of the Z-FAST/ZO-FAST trialsPresented at 11th St. Gallen Breast Cancer ConferenceMarch 11–14, 2009St. Gallen, Switzerland Abstract 132
   Google Scholar
• BrufskyAMBossermanLDCaradonnaRRZoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up resultsClin Breast Cancer200992778519433387
   PubMed Web of Science ®Google Scholar
• de BoerRBundredNEidtmannHThe effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the ZO-FAST study 5-year final follow-upPresented at 33rd Annual San Antonio Breast Cancer SymposiumDecember 8–12, 2010San Antonio, TX Poster P5-11-01
   Google Scholar
• ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FASTPresented at 32nd Annual San Antonio Breast Cancer SymposiumDecember 9–13, 2009San Antonio, TX Abstract 4082
   Google Scholar
• ColemanREThorpeHCCameronDAdjuvant treatment with zoledronic acid in stage II/III breast cancer. The AZURE trial (BIG 01/04)Presented at 33rd Annual San Antonio Breast Cancer SymposiumDecember 8–12, 2010San Antonio, TX Abstract S4–S5
   Google Scholar
• ColemanREWinterMCCameronDThe effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancerBr J Cancer20101021099110520234364
   PubMed Web of Science ®Google Scholar